Posted by Michael Wonder on 01 Jun 2021
BeyondSpring announces U.S. FDA acceptance and priority review of new drug application for plinabulin and G-CSF combination for the prevention of chemotherapy-induced neutropenia
1 June 2021 - The FDA has set a Prescription Drug User Fee Act target action date for 30 November 2021.
BeyondSpring today announced that the U.S. FDA has accepted for filing, and with priority review, the Company's new drug application seeking approval for use of plinabulin in combination with granulocyte colony-stimulating factor for the prevention of chemotherapy-induced neutropenia.
